- Home
- DBVT vs NEN Comparison
DBVT vs NEN Comparison
Compare DBVT & NEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- NEN
- Stock Information
- Founded
- DBVT 2002
- NEN 1977
- Country
- DBVT France
- NEN United States
- Employees
- DBVT N/A
- NEN N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- NEN Building operators
- Sector
- DBVT Health Care
- NEN Real Estate
- Exchange
- DBVT Nasdaq
- NEN Nasdaq
- Market Cap
- DBVT 260.5M
- NEN 262.4M
- IPO Year
- DBVT N/A
- NEN N/A
- Fundamental
- Price
- DBVT $9.87
- NEN $72.50
- Analyst Decision
- DBVT Buy
- NEN
- Analyst Count
- DBVT 4
- NEN 0
- Target Price
- DBVT $14.81
- NEN N/A
- AVG Volume (30 Days)
- DBVT 33.2K
- NEN 326.0
- Earning Date
- DBVT 11-05-2025
- NEN 01-01-0001
- Dividend Yield
- DBVT N/A
- NEN 6.67%
- EPS Growth
- DBVT N/A
- NEN 34.86
- EPS
- DBVT N/A
- NEN 4.59
- Revenue
- DBVT $3,800,000.00
- NEN $83,884,808.00
- Revenue This Year
- DBVT $1,743.46
- NEN N/A
- Revenue Next Year
- DBVT $1,045.66
- NEN N/A
- P/E Ratio
- DBVT N/A
- NEN $15.69
- Revenue Growth
- DBVT N/A
- NEN 4.96
- 52 Week Low
- DBVT $2.21
- NEN $71.00
- 52 Week High
- DBVT $12.78
- NEN $84.00
- Technical
- Relative Strength Index (RSI)
- DBVT 55.10
- NEN 60.23
- Support Level
- DBVT $9.58
- NEN $71.00
- Resistance Level
- DBVT $10.50
- NEN $72.00
- Average True Range (ATR)
- DBVT 0.51
- NEN 0.15
- MACD
- DBVT 0.07
- NEN 0.09
- Stochastic Oscillator
- DBVT 64.92
- NEN 100.00
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.